A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.
NCT06476808
This study is recruiting at 3 US sites in 2 states, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to evaluate the safety, tolerability, and efficacy of escalating doses of BMS-986463 in participants with select advanced malignant tumors.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- High-grade Serous Ovarian Carcinoma (HGSOC)
- Uterine Serous Carcinoma (USC)
- Non-small Cell Lung Cancer (NSCLC)
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Bristol-Myers Squibb
- Last updated on ClinicalTrials.gov
- July 20, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 2
- USC/Norris Comprehensive Cancer Center · Los Angeles, CA
- Valkyrie Clinical Trials · Los Angeles, CA
New Jersey · 1
- John Theurer Cancer Center at Hackensack University Medical Center · Hackensack, NJ
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.